[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Centre Hospitalier de Bethune\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":94},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100603111","diaphragm-response-in-elderly-for-acute-monitoring-100603111",false,"NCT07132268","Diaphragm Response in Elderly for Acute Monitoring","Using Diaphragmatic Ultrasound to Predict Acute Respiratory Distress (ARD) in Patients Aged 75 and Over Admitted to the Emergency Department for Acute Dyspnea : Prospective Multicenter Study.","DREAM","Inclusion Criteria:\n\n* Patients aged ≥ 75 years\n* Emergency admission for acute dyspnea\n* Requiring an emergency ultrsoung.\n\nExclusion Criteria:\n\n* Acute respiratory distress requiring immediate invasive or non-invasive ventilation\n* Respiratory rate ≥ 25 breaths\u002Fmin, and\u002For SpO2 ≤ 90% on room air, and\u002For PaO2 ≤ 60 mmHg\n* Known diaphragmatic paralysis\n* Patients with degenerative neuromuscular disease\n* State of shock: systolic blood pressure \\\u003C 90 mmHg and\u002For mean arterial pressure \\\u003C 65 mmHg and\u002For presence of skin mottling and\u002For CTR \\> 3s\n* Lactate levels \\> 2 mmol\u002FL\n* Hypercapnic respiratory acidosis (pH \\\u003C 7.38 and PaCO2 \\> 45 mmHg)\n* Dyspnea due to metabolic acidosis (e.g., diabetic ketoacidosis, renal failure)\n* Dyspnea of traumatic origin\n* Refusal to participate or inability to provide informed consent\n* Patients deprived of liberty\n* Patients under guardianship or curatorship","ALL","75 Years",{"count":20,"type":21},145,"ESTIMATED","OBSERVATIONAL","Acute dyspnea is a common cause of emergency department admissions among elderly patients. Acute respiratory failure is often multifactorial and requires rapid and reliable evaluation. Currently, management relies on clinical, biological, and radiological assessments, but diaphragmatic ultrasound could provide an additional tool for real-time respiratory function evaluation. This study aims to integrate this non-invasive technology into the initial assessment of patients to improve care pathways. Hypothesis : Diaphragmatic ultrasound enables reliable assessment of respiratory function and can predict the need for mechanical ventilation.",[25,26,27],"Acute Dyspnea","Acute Respiratory Failure","Diaphragmatic Ultrasound","NOT_YET_RECRUITING","2026-05-05",{"date":31,"type":32},"2026-05-06","ACTUAL",{"date":34,"type":21},"2026-06",{"date":36,"type":21},"2028-06",{"name":38,"class":39},"Centre Hospitalier de Bethune","NETWORK",9,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},"100511228","improved-hemodynamic-tolerance-of-intermittent-hemodialysis-sessions-in-intensive-care-unite-using-citrate--vs-acetate-based-dialysate-100511228","NCT05936710","Improved Hemodynamic Tolerance of Intermittent Hemodialysis Sessions in Intensive Care Unite Using Citrate- vs Acetate-based Dialysate","Improved Hemodynamic Tolerance of Intermittent Hemodialysis Sessions in Intensive Care Unite (ICU) Using Citrate- vs Acetate-based Dialysate","HEMODIACIDE","Inclusion Criteria:\n\n* Patient ≥ 18 years old\n* Patient hospitalized in an intensive care unit\n* Patient with acute renal failure defined by a KDIGO stage ≥ 1 and suspected non-obstructive\n* Patient at risk of per dialytic hypotension (capillary refill time ≥ 3 seconds and\u002For cardiovascular SOFA ≥ 1 and\u002For lactatemia \\> 2mmol\u002FL)\n* Indication for Extra Renal Replacement Therapy with IHD.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding woman\n* Known chronic renal insufficiency of any stage\n* Cardio-renal and hepato renal syndrome\n* Unstable hemodynamic state: refractory shock\n* Patient included in another interventional study likely to modify the hemodynamic state\n* Patient deprived of liberty\n* Patient under guardianship or curatorship\n* Patient not affiliated to a social security system","18 Years",{"count":51,"type":21},48,"INTERVENTIONAL",[54],"NA","During intermittent hemodialysis (IHD), the occurrence of intradialytic hemodynamic instability (IHI) is frequent in ICU and impacted morbidity and mortality. Bicarbonate dialysate buffer improves hemodynamic tolerance compared to acetate dialysate buffer. However, bicarbonate dialysate buffer still contains a lower concentration of acetate, which could contribute to hemodynamic instability. Recently, citrate-based dialysate in bicarbonate hemodialysis instead of acetate have been proposed. They have the appropriate authorizations for routine use. The aim of this study is to compare acetate- vs citrate-based dialysate in terms of hemodynamic tolerance and effectiveness.",[57],"Intradialytic Hypotension",[59,60,61,62],"citrate based dialysate","acetate based dialysate","hypotension","hemodynamic tolerance","RECRUITING",{"date":65,"type":32},"2026-05-08",{"date":67,"type":32},"2023-12-07",{"date":69,"type":21},"2027-07",{"name":38,"class":39},5,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":52,"phases":82,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":87,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},"100502099","phase-2-efficacy-of-early-intravenous-high-dose-vitamin-c-in-post-cardiac-arrest-shock-100502099","NCT05817851","Efficacy of Early Intravenous High-dose Vitamin C in Post-cardiac Arrest Shock.","Efficacy of Early Intravenous High-dose Vitamin C in Post-cardiac Arrest Shock: a Multicenter, Randomized Controled Trial.","VICEPAC","Inclusion Criteria:\n\n* patients still comatose (Glasgow coma scale \\\u003C 8) after an OHCA of presumed cardiac origin with ROSC \\\u003C 60 min;\n* and treated with a norepinephrin or an epinephrin continuous infusion during at least 30 min before randomization to maintain mean arterial pressure (MAP) ≥ 65 mmHg.\n\nExclusion Criteria:\n\n* patients still comatose (Glasgow coma scale \\\u003C 8) after an OHCA of presumed cardiac origin with ROSC \\\u003C 60 min;\n* and treated with a norepinephrin or an epinephrin continuous infusion ≥ 0.2µg\u002Fkg\u002Fh, within 4 hours after OHCA, during at least 30 min\u002Fh to maintain mean arterial pressure (MAP) ≥ 65 mmHg.\n\nExclusion criteria:\n\n* minor or pregnant women;\n* OHCA from evident extracardiac cause (trauma, bleeding, poisoning, etc.);\n* interval between RACS and randomization \\> 6 hours;\n* extracorporeal circulatory assistance requirement in the first 4 hours after OHCA;\n* history of urolithiasis, oxalate nephropathy or hemochromatosis;\n* glucose-6-phosphate deshydrogenase deficiency; nephrolithiasis, hyperoxalyurie\n* patients already treated with vit-C; known vit-C deficit;\n* inclusion in another study;\n* pre-existent severe chronic kidney disease (glomerular filtration rate \\\u003C 30ml\u002Fmin);\n* treatment limitationsor moribound\n* Patient with derpived freedom or with legal protective measures.\n* Patient not covered by French national health insurance",{"count":81,"type":21},234,[83],"PHASE2","Among patients admitted after an out-of-hospital cardiac arrest (OHCA) in intensive care unit (ICU), almost two thirds of patients will develop in the first hours a post-cardiac arrest (CA) shock. This post-CA shock, combines cardiac and hemodynamic failure, generally resulting in multi-organ failure and early death in up to 35% of patients. Experimental data suggest that intravenous ascorbic acid (vitamin C) may attenuate inflammation and vascular injury related to sepsis or surgery. Preclinical and clinical studies also provide safety data of high dose intravenous vitamin C (\\> 200mg\u002Fkg\u002Fday) with no significant adverse event reported and favorable impact on outcome. Experimental data also suggest beneficial effect of vitamin C in post-CA management with improvement of shock and multi-organ failure with potential benefit on neuroprotection and outcome.\n\nThe study is a phase II multicenter prospective controlled open-label trial randomized in two parallel groups :\n\n* Expérimental group: Standard of care care for post-CA shock + Vitamin C (Vit-C) 200mg\u002Fkg\u002Fd IV (started as early as possible, no later than 1 h after randomization + thiamin (Vit B1) 200mg every 12 h during 3 days.\n* Control group: Standard of care care for post CA shock according international guidelines.\n\nPatient number to be enrolled : 234, Study duration :24 months and 28 days, Inclusion duration : 24 months, Patient participation : duration : 28 days",[86],"Cardiac Arrest",{"date":65,"type":32},{"date":89,"type":32},"2023-12-27",{"date":91,"type":21},"2028-01-24",{"name":38,"class":39},14,""]